Clinicopathologic and molecular characteristics of lung adenocarcinoma arising in young patients

Journal of Korean Medical Science

Volumn 27, Issue 9, 2012, Pages 1027-1036

  Kim, Lucia ^a   Kim, Kyu Ho ^a   Yoon, Yong Han ^a   Ryu, Jeong Seon ^a   Choi, Suk Jin ^a   Park, In Suh ^a   Han, Jee Young ^a   Kim, Joon Mee ^a   Chu, Young Chae ^a  

^a Inha University School of Medicine   (South Korea)

Author keywords

Adenocarcinoma; Age groups; EGFR; EML4 ALK; Immunohistochemistry; Lung neoplasm

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ADENOCARCINOMA; ADULT; AGE; AGED; ARTICLE; CANCER STAGING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; SMOKING;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING;

EID: 84866370113     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2012.27.9.1027     Document Type: Article

References (31)

1. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, Park EC, Lee JS. Cancer statistics in Korea: Incidence, mortality and survival in 2006-2007. J Korean Med Sci 2010; 25: 1113-21.
2. Subramanian J, Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Piccirillo J, Govindan R. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol 2010; 5: 23-8.
3. Liu NS, Spitz MR, Kemp BL, Cooksley C, Fossella FV, Lee JS, Hong WK, Khuri FR. Adenocarcinoma of the lung in young patients. The M. D. Anderson experience. Cancer 2000; 88: 1837-41.
4. Green LS, Fortoul TI, Ponciano G, Robles C, Rivero O. Bronchogenic cancer in patients under 40 years old: the experience of a Latin American country. Chest 1993; 104: 1477-81.
5. Kuo C, Chen Y, Chao J, Tsai C, Perng R. Non-small cell lung cancer in very young and very old patients. Chest 2000; 117: 354-7.
6. Blanco M, Garcia-Fontan E, Rivo JE, Repaaz JR, Obeso GA, Canizares MA. Bronchogenic carcinoma in patients under 50 years old. Clin Transl Oncol 2009; 11: 322-5.
7. Skarin AT, Herbst RS, Leong TL, Bailey A, Sugarbaker D. Lung cancer in patients under age 40. Lung Cancer 2001; 32: 255-64.
8. Tian DL, Liu HX, Zhang L, Yin HN, Hu YX, Zhao HR, Chen DY, Han LB, Li Y, Li HW. Surgery for young patients with lung cancer. Lung Cancer 2003; 42: 215-20.
9. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-11.
10. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
11. Zakowski MF, Hussain S, Pao W, Ladanyi M, Ginsberg MS, Heelan R, Miller VA, Rusch VW, Kris MG. Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors Erlotinib and Gefitinib. Arch Pathol Lab Med 2009; 133: 470-7.
12. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, Gerald WL, and Travis WD. Lung adenocarcinoma: Modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008; 32: 810-27.
13. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-53.
14. Paik JH, Choe G, Kim H, Choe J, Lee HJ, Lee C, Lee JS, Jheon S, Chung J. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: Correlation with fluorescence in situ hybridization. J Thorac Oncol 2011; 6: 466-72.
15. Raz DJ, Jablons DM. Bronchioloalveolar carcinoma is not associated with younger age at diagnosis: an analysis of the SEER database. J Thorac Oncol 2006; 1: 339-43.
16. Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009; 15: 3023-8.
17. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010; 12: 169-76.
18. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Lung. In: Edge SB, editor. AJCC cancer staging manual. 7th ed. New York: Springer, 2010, p253-66.
19. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus and heart. In: Kleihues P, Sobin LH, editors. World Health Organization classification of tumours. Lyon: IARCPress, 2004, p35-44.
20. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, et al. International Aassociation for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary Classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-85.
21. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, Kondo H, Shimosato Y. Small adenocarcinoma of the lung. Cancer 1995; 75: 2844-52.
22. Nakano H, Soda H, Takasu M, Tomonaga N, Yamaguchi H, Nakatomi K, Fujino S, Hayashi T, Nakamura Y, Tsukamoto K, et al. Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer 2008; 60: 136-40.
23. Kish JK, Ro JY, Ayala AG, McMurtrey MJ. Primary mucinous adenocarcinoma of the lung with signet-ring cells: a histochemical comparison with signet-ring cell carcinomas of other sites. Hum Pathol 1989; 20: 1097-102.
24. Tsuta K, Ishii G, Yoh K, Nitadori J, Hasebe T, Nishiwaki Y, Endoh Y, Kodama T, Nagai K, Ochiai A. Primary lung carcinoma with signet-ring cell carcinoma components: clinicopathological analysis of 39 cases. Am J Surg Pathol 2004; 28: 868-74.
25. Iwasaki T, Ohta M, Lefor AT, Kawahara K. Signet-ring cell carcinoma component in primary lung adenocarcinoma: potential prognostic factor. Histopathology 2008; 52: 639-40.
26. Lindstrom I, Nordling S, Nissen A, Tammilehto L, Mattson K, Knuutila S. DNA copy number changes in lung adenocarcinoma in younger patients. Mod Pathol 2002; 15: 372-8.
27. Kondou M, Nagayasu T, Hidaka S, Tsuchiya T, Takeshita H, Yasutake T, Yano H, Minami H, Iwasaki K. Correlation between angiogenesis and p53 expression in lung adenocarcinoma of young patients. Tohoku J Exp Med 2009; 217: 101-7.
28. Shaw AT, Costa DB, Iafrate AJ, Dezube BJ, Shapiro GI, Bang YJ, Janne PA, Lynch TJ, Maki RG, Gamidge DR, et al. Clinical activity of the oral ALK and MET inhibitor PF-02341066 in non-small cell lung cancer (SNCLC) with EML4-ALK translocations. J Thorac Oncol 2009; 4: S305-6.
29. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15: 5216-23.
30. Jakobsen JN, Sorensen JB. Intratumor heterogeneity and chemotherapyinduced changes in EGFR status in non-small cell lung cancer. Cancer Chemother Pharmacol 2012; 69: 289-99.
31. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutation is extremely rare in lung adenocarcinoma. J Clin Oncol 2011; 29: 2972-7.